Peripheral nervous system

Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity

Retrieved on: 
Thursday, May 4, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, HTRS, CHDI, Bachelor of Medicine, Bachelor of Surgery, Patisiran, PEG, Haemophilia, APOLLO, Acquisition, Patient, RNA interference, Cardiomyopathy, Brazilian Health Regulatory Agency, Polyneuropathy, The Lancet, Tissue, Therapy, NASH, Quarter, Corporate social responsibility, Brain, Medication, Randomness, Corporation, Liver, Growth, Innovation, Lancet, Viral hepatitis, Conference, Eos, Safety, ANVISA, Workplace, AHP, Hepatitis B virus, Truly Madly Deeply – Ultra Rare Tracks, Gene silencing, Shanda, Sanofi, HBV, Central nervous system, CER, Regeneron Pharmaceuticals, RTE, SAD, CNS, Peripheral nervous system, TTR, ATTR, Amyloidosis, Hemostasis, Pharmaceutical industry, Vaccine, Management, Cryptocurrency, Inclisiran, Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights.

Key Points: 
  • Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights.
  • Attained over 3,160 hATTR amyloidosis patients with polyneuropathy worldwide on commercial treatment with ONPATTRO or AMVUTTRA as of March 31, 2023.
  • Alnylam announces today that it intends to present 18-month results from the APOLLO-B Phase 3 study of patisiran at ESC-HF 2023, being held May 20-23, 2023 in Prague.
  • Financial Results for the Quarter Ended March 31, 2023

Newron to Present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Wednesday, May 3, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, CINP, TRS, XETRA, CNS, Clozapine, Medication, Congress, Queen Elizabeth, Westin Harbour Castle Hotel, Schizophrenia International Research Society, Fairmont Royal York, 34th Special Operations Squadron, Patient, SIRS, Peripheral nervous system, Pharmaceutical industry

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announced that it will present six posters in various presentation formats at the upcoming 34th CINP World Congress of Neuropsychopharmacology, taking place 7-10 May 2023 at the Fairmont The Queen Elizabeth hotel in Montreal, Québec, Canada, and the 2023 Congress of the Schizophrenia International Research Society (SIRS) taking place 11-15 May 2023 at The Westin Harbour Castle in Toronto, Ontario, Canada.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announced that it will present six posters in various presentation formats at the upcoming 34th CINP World Congress of Neuropsychopharmacology, taking place 7-10 May 2023 at the Fairmont The Queen Elizabeth hotel in Montreal, Québec, Canada, and the 2023 Congress of the Schizophrenia International Research Society (SIRS) taking place 11-15 May 2023 at The Westin Harbour Castle in Toronto, Ontario, Canada.
  • The posters and presentations will feature first-time disclosures of additional results from study 014/015, an international, randomized, open label, rater-blinded study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS not responding to their current antipsychotic medication.
  • These results offer further analyses of the multidimensional efficacy of glutamate release modification in patients with TRS and the characteristics of early and late responders in patients with TRS, thus deepening the understanding of the potential long-term benefits an innovative add-on therapy that modifies glutamate release could offer to TRS patients.
  • “Evenamide Added On To Antipsychotics In Patients With TRS Is Associated With Significant Efficacy: Results From A Pilot, 6-week, Phase 2 Study”
    “Characteristics Of Early And Late Responders To Evenamide Add-on In TRS Patients Not Responding To An Antipsychotic: Results From A Phase 2 Study”

EQS-News: Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Wednesday, May 3, 2023
CINP, International, CET, TRS, XETRA, CNS, Clozapine, Congress, Queen Elizabeth, Westin Harbour Castle Hotel, Schizophrenia International Research Society, Fairmont Royal York, 34th Special Operations Squadron, Patient, SIRS, Peripheral nervous system, Pharmaceutical industry

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The posters and presentations will feature first-time disclosures of additional results from study 014/015, an international, randomized, open label, rater-blinded study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS not responding to their current antipsychotic medication.
  • These results offer further analyses of the multidimensional efficacy of glutamate release modification in patients with TRS and the characteristics of early and late responders in patients with TRS, thus deepening the understanding of the potential long-term benefits an innovative add-on therapy that modifies glutamate release could offer to TRS patients.
  • “Evenamide Added On To Antipsychotics In Patients With TRS Is Associated With Significant Efficacy: Results From A Pilot, 6-week, Phase 2 Study”
    “Characteristics Of Early And Late Responders To Evenamide Add-on In TRS Patients Not Responding To An Antipsychotic: Results From A Phase 2 Study”

Newron Announces Senior Management Team Changes

Retrieved on: 
Tuesday, May 2, 2023
Biotechnology, Pharmaceutical, Health, Neurology, Business development, IPO, Finance department, Punjab (Pakistan), XETRA, CNS, Medication, Retirement, Patient, Senior management, CFO, EIB, Ministry of Finance, Peripheral nervous system, Management, Newron Cup

Roberto Galli, Vice President Finance since 2012, has been promoted to Chief Financial Officer as of July 1, 2023.

Key Points: 
  • Roberto Galli, Vice President Finance since 2012, has been promoted to Chief Financial Officer as of July 1, 2023.
  • At the same time, we warmly welcome Laura to the Senior Management Team at Newron and look forward to working with her in the future.
  • He joined Newron in November 2002 and has held several management positions within the Finance Department before being appointed Vice President Finance in June 2012.
  • Roberto was involved in the Company’s IPO, strategic corporate transactions, and was instrumental in finalizing the EIB funding facility.”

EQS-News: Newron announces Senior Management Team changes

Retrieved on: 
Tuesday, May 2, 2023
Business development, IPO, Finance department, Punjab (Pakistan), CET, XETRA, CNS, Retirement, Patient, Senior management, CFO, EIB, Ministry of Finance, Peripheral nervous system, Management, Newron Cup

Roberto Galli, Vice President Finance since 2012, has been promoted to Chief Financial Officer as of July 1, 2023.

Key Points: 
  • Roberto Galli, Vice President Finance since 2012, has been promoted to Chief Financial Officer as of July 1, 2023.
  • At the same time, we warmly welcome Laura to the Senior Management Team at Newron and look forward to working with her in the future.
  • He joined Newron in November 2002 and has held several management positions within the Finance Department before being appointed Vice President Finance in June 2012.
  • Roberto was involved in the Company’s IPO, strategic corporate transactions, and was instrumental in finalizing the EIB funding facility.”

Hansa Biopharma interim report January-March 2023

Retrieved on: 
Thursday, April 20, 2023
Inflammation, International, CET, Senior, Hansa, Hope, SOC, Confidant, Patient, Immunoglobulin G, GBS, Kidney, Kidney transplantation, CFO, Immunology, Rare, Transplant, News, Peripheral nervous system, Management, Dentistry, Pharmaceutical industry, Nursing, Internet service provider, Pfizer

Søren Tulstrup, President and CEO of Hansa Biopharma, comments

Key Points: 
  • Søren Tulstrup, President and CEO of Hansa Biopharma, comments
    "Hansa's commercial efforts for Idefirix® in Europe continue to progress as planned.
  • H1 2023            Anti-GBM Phase 3: First patient enrolled
    H2 2023            Long-term follow-up study in kidney transplantation: 5-year data readout
    H2 2023            AMR Phase 2: Full data readout
    H2 2023            GBS Phase 2: First data readout
    Hansa Biopharma will host a telephone conference today Thursday April 20, 2023, 14:00 CET / 8:00am EST.
  • The presentation will be held in English and be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota.
  • To participate in the telephone conference, please use the dial-in details provided below:
    The interim report and latest investor presentation can be downloaded from our web:
    Investor road show presentation Q1, 2023 https://www.hansabiopharma.com/investors/presentations/
    This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.

EQS-News: Newron announces AGM 2023 results  

Retrieved on: 
Tuesday, April 18, 2023
D, XETRA, AGM, Don, CNS, Incident management team, Patient, Senior management, Knowledge, R, Peripheral nervous system, Management

Milan, Italy, April 18, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announces that its shareholders approved all motions on the agenda of the AGM 2023 held today.

Key Points: 
  • Milan, Italy, April 18, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announces that its shareholders approved all motions on the agenda of the AGM 2023 held today.
  • Ulrich Köstlin, Chairman of the Board of Directors of Newron, commented: “We thank all our shareholders for their ongoing and longstanding support and trust”.
  • At the same time, we welcome Gillian Dines as newly elected Board member and Chairwoman of the R&D committee.
  • We are looking forward to working with her and are convinced that her profound R&D knowledge and entrepreneurial personality will be an asset to Newron”.

Trevena Reports Fourth Quarter 2022 Results and Provides Business Update

Retrieved on: 
Thursday, March 30, 2023
Epilepsy, Vomiting, Male, Cleveland Clinic, Central nervous system, Senior, Delirium, ARTEMIS, Atrium Health Wake Forest Baptist, EMR, Trevena, PACU, Confusion Assessment Method, CNS, Richmond Agitation-Sedation Scale, Sale, Incidence, Data analysis, Length of stay, Patient, Central nervous system disease, Risk, Nausea, Webcast, Transcranial magnetic stimulation, Hospital, Richmond, Abdominal ultrasonography, GI, S1P, Antiemetic, Peripheral nervous system, Nursing, Pharmaceutical industry, Cryptocurrency, Electroencephalography

CHESTERBROOK, Pa., March 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today reported its financial results for the fourth quarter ended December 31, 2022 and provided an overview of its recent operational highlights.

Key Points: 
  • As reference, in pooled data for the Company’s pivotal Phase 3 studies of OLINVYK, the GI complete response rate was 46.2% (0.35mg) and 39.7% (0.50mg).
  • Analysis of respiratory data from VOLITION is not yet available, and the Company expects to report these data mid-2023.
  • In the fourth quarter of 2022, the commercial team signed contracts with three new specialty distributors that focus primarily on ambulatory surgery centers (ASCs).
  • Cash and cash equivalents were $38.3 million as of December 31, 2022, which the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the fourth quarter of 2023.

AlgoTx Progresses ATX01 in Two Indications

Retrieved on: 
Thursday, March 30, 2023
Biotechnology, FDA, Health, Clinical Trials, Oncology, ACT, Exercise, Erythromelalgia, Mayo Clinic, EU, Spinal cord, University of Erlangen–Nuremberg, Skin, Hope, Brain, CIPN, EMA, Pain, Nav1.7, Patient, Swelling, EASE, Clinical professor, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Red, Food, Nav1.8, Peripheral nervous system, Pharmaceutical industry

Meanwhile, the first patients have been randomized into the “ATX01 for the pain of ChemoTherapy” (ACT) study in Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Key Points: 
  • Meanwhile, the first patients have been randomized into the “ATX01 for the pain of ChemoTherapy” (ACT) study in Chemotherapy-Induced Peripheral Neuropathy (CIPN).
  • Both programs have been granted Fast Track Designation by the FDA.
  • AlgoTx is conducting the ACT study as part of its US / EU Phase 2 program in the indication of CIPN.
  • AlgoTx has obtained an Orphan Disease Designation from both FDA and EMA to support development of ATX01 in this indication.

EQS-News: Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry

Retrieved on: 
Tuesday, March 28, 2023
PANSS, CET, Schizophrenia, TRS, XETRA, Positive, Clinical Global Impression, CNS, Clozapine, Congress, Incidence, Insomnia, Patient, European, NCE, Fever, Peripheral nervous system, Risk management, Pharmaceutical industry, Silviculture, Psychiatry

The first poster presented full results from the cohort of the first 100 patients completing six months/endpoint of treatment with evenamide in study 014/015.

Key Points: 
  • The first poster presented full results from the cohort of the first 100 patients completing six months/endpoint of treatment with evenamide in study 014/015.
  • Study 014/015 is an international, randomized, open label, rater-blinded study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS) not responding to their current antipsychotic medication.
  • 97% of patients completed six weeks of treatment, and more than 90% of the completers chose to continue with evenamide treatment into the long-term extension study (study 015).
  • The second poster detailed the characterization of “Responder” in TRS patients based on data from this study.